Rovelizumab

Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke[1].

[1] Jones R. Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6. PMID:16100700
[2] Qualls JE, et al. A double agent in cancer: stopping macrophages wounds tumors. Nat Med. 2010 Aug;16(8):863-4. DOI:10.1038/nm0810-863